After Hours Decliner
CLDX Celldex Therapeutics35.66+0.24+0.7%
After Hours:33.14-2.52 (-7.1%)
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Globe NewswireTue, 21-Jul 4:01 PM
After Hours Decliner
CLDX Celldex Therapeutics31.26-0.46-1.5%
After Hours:30.18-1.08 (-3.5%)
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
Globe NewswireWed, 1-Apr 9:48 PM
After Hours Decliner
CLDX Celldex Therapeutics31.26-0.46-1.5%
After Hours:29.60-1.66 (-5.3%)
Celldex Announces Proposed Public Offering of Common Stock
Globe NewswireWed, 1-Apr 4:01 PM
CLDX Celldex Therapeutics22.91-0.66 (-2.8%)
CLDX Celldex Therapeutics24.51-0.09 (-0.4%)
Premarket Decliner
CLDX Celldex Therapeutics24.02-0.46-1.9%
Premarket:21.08-2.94 (-12.2%)
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
Globe NewswireTue, 19-Aug 4:01 PM
